Updates in the treatment of ocular allergies

Journal of Asthma and Allergy

Volumn 3, Issue , 2010, Pages 149-158

  Kari, Osmo ^a   Saari, K Matti ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Allergic blepharitis; Allergic conjunctivitis; Atopic keratoconjunctivitis; Eosinophils; Vernal keratoconjunctivitis

Indexed keywords

EID: 85013867637     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S13705     Document Type: Review

References (40)

1. Key B. Allergy and allergic diseases. Part I. N Engl J Med. 2001;344: 30-37.
2. Ono SJ, Abelson MB. Allergic conjunctivitis update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115(1): 118-122.
3. Hussain A, Awan H, Khan MD. Prevalence of non-vision-impairing conditions in a village in Chakwal district, Punjab, Pakistan. Ophthalmic Epidemiol. 2004;11(5):413-426.
4. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153 Suppl 1:17-21.
5. Ibáñez MD, Garde JM. Allergy in patients under fourteen years of age in Alergológica. J Investig Allergol Clin Immunol. 2009;19 Suppl 2: 61-68.
6. Saari KM, Kari O, Haahtela T. Nonallergic eosinophilic conjunctivitis. Expert Rev Ophthalmol. 2007;2(3):331-333.
7. Kari O, Haahtela T, Laine P, et al. Cellular characteristics of nonallergic eosinophilic conjunctivitis. Acta Ophthalmol. 2010;88(2): 245-250.
8. Reitamo S, Remitz A, Haahtela T. Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy. 2009;64(4): 503-504.
9. Malo J-L, Lemiére C, Desjardins A, Cartier A. Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma. Eur Respir J. 1997;10(7):1513-1515.
10. Irani AM. Ocular mast cells and mediators. Immunol Allergy Clin North Am. 2008;28(1):25-42, v.
11. Ikoma A. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis. J Pharmacol Sci. 2009; 110(3):265-269.
12. Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets. 2010;9(3): 173-180.
13. McGill JI, Holgate ST, Church MK, Anderson DF, Bacon A. Allergic eye disease mechanisms. Br J Ophthalmol. 1998;82(10): 1203-1214.
14. Spencer LA, Szela CT, Perez SA, et al. Human eosinophils constitutively express multiple Th1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol. 2009;85(1): 117-123.
15. Corthay A. How do regulatory T cells work? Scand J Immunol. 2009; 70(4):326-336.
16. Gill D, Tan PH. Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. Expert Opin Ther Targets. 2010;14(8):797-824.
17. Fukushima A, Ozaki A, Fukata K, Ishida W, Ueno H. Ag-specific recognition, activation, and effector function of T cells in the conjunctiva with experimental immune-mediated blepharoconjunctivitis. Invest Ophthalmol Vis Sci. 2003;44(10):4366-4374.
18. Kari O, Salo OP, Halmepuro L, Suvilehto K. Tear histamine during allergic conjunctivitis challenge. Graefes Arch Clin Exp Ophthalmol. 1985;223(2):60-62.
19. de Paulis A, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol. 1992;99(6):723-728.
20. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanism of action and applications in dermatology. Clin Exp Dermatol. 2002;27(7):555-561.
21. Aramburu J, Heitman J, Crabtree GR. Calcineurin: a central controller of signalling in eukaryotes. EMBO Rep. 2004;5(4):343-348.
22. Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):445-448.
23. Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophtalmol Scand. 2006;84(5):693-695.
24. Frati F, Scurati S, Puccinelli P, et al. Development of sublingual allergy vaccine for grass pollinosis. Drug Des Devel Ther. 2010;4:99-105.
25. Okubo K, Nagakura T. Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update. Allergol Int. 2008;57(3):205-209.
26. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
27. Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3): 660-666.
28. Malling H-J, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009; 39(3):387-393.
29. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy. 2009;64 Suppl 91:1-59.
30. Broide DH. Immunomodulation of allergic disease. Annu Rev Med. 2009;60:279-291.
31. Kopp MV, Hamelmann E, Zielen S, et al; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009; 39(2):271-279.
32. Remitz A, Virtanen HM, Reitamo S, Kari O. Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure. Acta Ophthalmol. 2010 Jan 8 [Epub ahead of print].
33. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144-156.
34. Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25(4):365-372.
35. Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010;26(2): 165-174.
36. Kari O, Haahtela T. Conjunctival eosinophilia in atopic and non-atopic external eye symptoms. Acta Ophthalmol (Copenh). 1992;70(3): 335-340.
37. Ponikaus JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma? J Allergy Clin Immunol. 2003; 112(5):877-882.
38. Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med. 1994;150(4): 1038-1048.
39. Kari O. Atopic conjunctivitis. A cytologic examination. Acta Ophthalmol (Copenh). 1988;66(4):381-386.
40. Feser A, Mahler V. Periorbital dermatitis: causes, differential diagnoses and therapy. J Dtsch Dermatol Ges. 2010;8(3):159-166.